Table 1 M-protein and serum free light-chain levels during IL-1 inhibition
From: The role of interleukin-1 beta in the pathophysiology of Schnitzler’s syndrome
Patient | Sex | Treatment | M-protein | Serum free light-chains | |||
|---|---|---|---|---|---|---|---|
number | subtype | g/L | kappa (mg/l) | lambda (mg/l) | Ratio κ / λ | ||
1 | M | Anakinra | IgMκ & IgMλ | 10.1 | 14.4 | 46.8 | 0.31 |
None (Day 4 after anakinra withdrawal) | 7.7 | 14.7 | 53.9 | 0.27 | |||
Canakinumab day 28 | 10.6 | 18.6 | 51.0 | 0.36 | |||
Relapse (post-canakinumab) | 9.3 | ||||||
2 | F | None (pre-anakinra) | IgGκ | 6.8 | 88.3 | 12.4 | 7.12 |
Anakinra | 5 | 59.9 | 9.4 | 6.35 | |||
None (day 5 after anakinra withdrawal) | 4.1 | 69 | 13.5 | 5.11 | |||
Canakinumab Day 28 | 4.3 | 59.1 | 11.6 | 5.09 | |||
Relapse (post-canakinumab) | 3.7 | 78.4 | 12.2 | 6.43 | |||
3 | M | None (day 5 after anakinra withdrawal) | IgMκ | 2.7 | |||
Canakinumab day 28 | 3.5 | 19.1 | 19.8 | 0.96 | |||
4 | M | Anakinra | IgGκ | 2.9 | |||
None (day 5 after anakinra withdrawal) | 2.8 | ||||||
Canakinumab day 28 | 3.2 | 14 | 10.3 | 1.36 | |||
Relapse (post-canakinumab) | 2.5 | ||||||
5 | M | Anakinra | IgMκ | 4.4 | |||
None (day 6 after anakinra withdrawal) | 4.5 | 19.4 | 12.4 | 1.56 | |||
Canakinumab day 28 | 5 | ||||||
Relapse (post-canakinumab) | |||||||
6 | M | Anakinra | IgMκ | 6.8 | 25.5 | 20.6 | 1.24 |
None (day 4 after anakinra withdrawal) | 6.1 | 29.2 | 15.8 | 1.85 | |||
Canakinumab day 28 | 5.6 | 29.3 | 17.9 | 1.64 | |||
Relapse (post-canakinumab) | 6.3 | ||||||
7 | F | Anakinra | IgGκ | n.d. | |||
None (day 3 after anakinra withdrawal) | n.d. | 15.3 | 15.1 | 1.01 | |||
Canakinumab day 28 | n.d. | ||||||
Relapse (post-canakinumab) | n.d. | ||||||
8 | M | Anakinra | IgGκ | n.d. | 17 | 13.5 | 1.26 |
None (day 5 after anakinra withdrawal) | n.d. | 26.9 | 18.7 | 1.44 | |||
Canakinumab day 14 | p.n.q. | 18.4 | 18.1 | 1.02 | |||
Canakinumab day 28 (relapse) | p.n.q. | 23.9 | 23.2 | 1.03 | |||